Bhavna Hunjan Appointed to the Board as Chief Business Officer


C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

1 February 2022 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Bhavna Hunjan to the Board of Directors, as Chief Business Officer, with immediate effect.

Bhavna joined C4XD in 2016 and, since becoming Head of Corporate Strategy and Development in 2017, has played a critical role in a series of successful licensing deals and strategic partnerships, as well as driving business growth and capital raising as part of the Executive Management team.  In her new role, Bhavna will be responsible for shaping the strategic direction of C4XD.  She will lead corporate development activities including developing and executing C4XD’s deal strategy to build shareholder value, intelligence-driven strategic planning, commercial evaluation of new projects and alliances, and she will represent C4XD in external activities including investor relations, fundraising, M&A, and external communications.

Bhavna was named a Rising Star in the Movers & Shakers in BioBusiness 2017 and voted one of the 30 Rising Leaders in Life Sciences 2020 by In Vivo.  Previously, Bhavna spent 15 years in commercial and corporate roles at Lehman Brothers, Nomura International, PwC and Cancer Research UK.  She holds a first-class Masters degree in Biochemistry from the University of Oxford.

In addition, Emma Blaney has been promoted to Chief Operating Officer.  Emma joined C4XD in 2014 as a Senior Programme Manager and became VP Operations in 2016.  In her new role, Emma will oversee operations, governance and policies as well as portfolio management, employee productivity and building on the Company’s highly inclusive culture.  Emma has a PhD in Synthetic Organic Chemistry from the University of Leeds, and a first-class Chemistry and Pharmacology degree from the University of Liverpool.

Eva-Lotta Allan, Chairman of C4X Discovery, commented:

“I am delighted to announce these two key appointments today.  Bhavna has been instrumental in steering the Company over the past six years to where we are today.  Her business acumen, married with her ability to drive deals to commercial success and understanding of how the markets operate, has helped to build C4XD into a strong, commercial Drug Discovery company.  Bhavna joining the Board is a natural step and reflects the key role she plays within the management team; I look forward to working with her in the coming years.

“Furthermore, promoting Emma to COO was an easy choice. Emma first joined C4XD as a chemist and has grown into an incredible Operations Manager, keeping a steady ship at all times and running the business on a day-to-day basis with the utmost attention to detail and care.  The positive impact Emma and Bhavna have had on the business overall has been fundamental to the success of the Company.”

Additional Disclosures

Bhavna Hunjan (aged 36) holds options over 655,556 ordinary shares in the Company which have been granted to her during the course of her employment.

There is no further information regarding Bhavna Hunjan required to be disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies, other than those disclosed above.

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.